VIP
Immunomodulatory and vasodilator neuropeptide; serious clinical use has been mostly inhaled and in niche applications, not the generic vial.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
VIP is a 28 aa peptide of the secretin/glucagon family. It relaxes smooth muscle, dilates vessels, and immunomodulates (often toward regulatory profiles). There is human literature on PH and pulmonary inflammation with inhaled VIP; injectable “VIP research” products do not automatically inherit those protocols.
Studied for
How it works
VPAC1/VPAC2 receptors (Gs → cAMP). Bronchodilator, vasodilator, and immunoregulatory effects (e.g., increase in Tregs in BAL in a sarcoidosis study).
What the research says
Small studies in primary pulmonary hypertension (JCI / PubMed 12727925). Inhaled sarcoidosis (PubMed 20442436). Aviptadil programs in COVID/ARDS with mixed results depending on the trial. Short half-life → delivery challenge.
Evidence level
C — small/niche human studies; no general approval
What's most reported
- Hemodynamic/effort improvement in small PH series
- Immune changes in BAL (inhaled sarcoidosis)
- Community: “mold / CIRS / immune” — anecdotal
Common side effects
Hypotension, flushing, tachycardia possible due to vasodilation; irritation depending on the route. Profile of research vials is poorly characterized.
Combines / does not combine
Caution with vasodilators/antihypertensives. No validated clinical stacks of the “detox” type.
Frequently asked questions
Not as a general standard.
Not necessarily: different exposure and evidence.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Research products are not approved drugs unless otherwise indicated.